Allurion Scales Up AI-Enabled Weight-Loss Platform

article image

Device company Allurion recently went public through a SPAC co-led by the former CEO and executive chair of Medtronic, to increase market penetration of its intragastric balloon and expand its weight-loss care suite for patients and providers.

In August, Allurion Technologies went public via a SPAC (special purpose acquisition company) transaction, raising $100 million, $30 million more than it originally set out to raise when it first announced the deal in February 2023. The complex deal involved a merger with Compute Health, which, chaired by Omar Ishrak, PhD, the former CEO and executive chairman of Medtronic, went public in 2021 with the sole purpose of accomplishing such a business combination.

Allurion is thus prepared to float on the rising tide created by the introduction of the effective GLP-1 class of weight-loss drugs, heavily promoted by billions of dollars in direct-to-consumer advertising by their pharmaceutical developers. According to Allurion CEO Shantanu Gaur, MD, “That has created a tremendous amount of awareness around obesity as a disease and of weight loss as something that should be administered by a physician in a medical practice. Millions of people are now coming into this ecosystem of medical weight loss.”


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: